147 related articles for article (PubMed ID: 21731047)
21. Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer.
Bianchini D; de Bono JS
Eur J Cancer; 2011 Sep; 47 Suppl 3():S189-94. PubMed ID: 21943974
[No Abstract] [Full Text] [Related]
22. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
23. [Discovery of drug targets by quantitative proteomics and their clinical application].
Tomonaga T
Nihon Yakurigaku Zasshi; 2017; 149(3):123-127. PubMed ID: 28260742
[No Abstract] [Full Text] [Related]
24. New drugs for prostate cancer.
Alifrangis C; O'Hanlon-Brown C; Tuthill M; Waxman J
BJU Int; 2012 Jun; 109(12):1801-6. PubMed ID: 21933331
[TBL] [Abstract][Full Text] [Related]
25. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
Evaul K; Li R; Papari-Zareei M; Auchus RJ; Sharifi N
Endocrinology; 2010 Aug; 151(8):3514-20. PubMed ID: 20534728
[TBL] [Abstract][Full Text] [Related]
26. New approaches to targeting the androgen receptor pathway in prostate cancer.
Velho PI; Bastos DA; Antonarakis ES
Clin Adv Hematol Oncol; 2021 Apr; 19(4):228-240. PubMed ID: 33989272
[TBL] [Abstract][Full Text] [Related]
27. Targeting advanced prostate cancer.
Fillon M
J Natl Cancer Inst; 2011 Dec; 103(23):1733. PubMed ID: 22100582
[No Abstract] [Full Text] [Related]
28. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets.
Tenhagen M; van Diest PJ; Ivanova IA; van der Wall E; van der Groep P
Endocr Relat Cancer; 2012 Aug; 19(4):R115-29. PubMed ID: 22508544
[TBL] [Abstract][Full Text] [Related]
29. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran C; Ouk S; Clegg NJ; Chen Y; Watson PA; Arora V; Wongvipat J; Smith-Jones PM; Yoo D; Kwon A; Wasielewska T; Welsbie D; Chen CD; Higano CS; Beer TM; Hung DT; Scher HI; Jung ME; Sawyers CL
Science; 2009 May; 324(5928):787-90. PubMed ID: 19359544
[TBL] [Abstract][Full Text] [Related]
30. Drug discovery in prostate cancer mouse models.
Valkenburg KC; Pienta KJ
Expert Opin Drug Discov; 2015; 10(9):1011-24. PubMed ID: 26027638
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays.
Zhou W; Duan M; Fu W; Pang J; Tang Q; Sun H; Xu L; Chang S; Li D; Hou T
Genomics Proteomics Bioinformatics; 2018 Dec; 16(6):416-427. PubMed ID: 30639122
[TBL] [Abstract][Full Text] [Related]
32. Targeting the androgen receptor in prostate cancer.
Culig Z
Expert Opin Pharmacother; 2014 Jul; 15(10):1427-37. PubMed ID: 24890318
[TBL] [Abstract][Full Text] [Related]
33. Network pharmacology for cancer drug discovery: are we there yet?
Azmi AS
Future Med Chem; 2012 May; 4(8):939-41. PubMed ID: 22650234
[No Abstract] [Full Text] [Related]
34. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells.
Matsuda T; Junicho A; Yamamoto T; Kishi H; Korkmaz K; Saatcioglu F; Fuse H; Muraguchi A
Biochem Biophys Res Commun; 2001 Apr; 283(1):179-87. PubMed ID: 11322786
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor modulators: a review of recent patents and reports (2012-2018).
Fujii S; Kagechika H
Expert Opin Ther Pat; 2019 Jun; 29(6):439-453. PubMed ID: 31092069
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapy in the treatment of castration-resistant prostate cancer.
Derleth CL; Yu EY
Oncology (Williston Park); 2013 Jul; 27(7):620-8. PubMed ID: 23977754
[TBL] [Abstract][Full Text] [Related]
37. New Therapeutic Target for Prostate Cancer.
Cancer Discov; 2016 Jun; 6(6):OF6. PubMed ID: 27091858
[TBL] [Abstract][Full Text] [Related]
38. New strategies for medical management of castration-resistant prostate cancer.
Asmane I; Céraline J; Duclos B; Rob L; Litique V; Barthélémy P; Bergerat JP; Dufour P; Kurtz JE
Oncology; 2011; 80(1-2):1-11. PubMed ID: 21577012
[TBL] [Abstract][Full Text] [Related]
39. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
Middleman MN; Lush RM; Figg WD
Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
[TBL] [Abstract][Full Text] [Related]
40. Paul Workman: Drugging the Cancer Genome.
Trends Cancer; 2016 Oct; 2(10):544-548. PubMed ID: 27904887
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
